GeneOne Life Science, Inc.

KSE 011000.KS

GeneOne Life Science, Inc. Free Cash Flow Yield on January 14, 2025: -16.17%

GeneOne Life Science, Inc. Free Cash Flow Yield is -16.17% on January 14, 2025, a -19.80% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • GeneOne Life Science, Inc. 52-week high Free Cash Flow Yield is -8.60% on August 19, 2024, which is 46.85% above the current Free Cash Flow Yield.
  • GeneOne Life Science, Inc. 52-week low Free Cash Flow Yield is -19.63% on December 26, 2024, which is -21.42% below the current Free Cash Flow Yield.
  • GeneOne Life Science, Inc. average Free Cash Flow Yield for the last 52 weeks is -15.27%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
KSE: 011000.KS

GeneOne Life Science, Inc.

CEO Mr. Young-Keun Park J.D., M.B.A.
IPO Date Feb. 4, 2000
Location South Korea
Headquarters The Pinnacle Gangnam
Employees 73
Sector Health Care
Industries
Description

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the development and contract manufacturing of gene-based-biomedicines. Its products comprise GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company also develops GLS-3000 and GLS-5310 for the treatment of SARS-CoV-2; GLS-5100 to treat VZV-Shingles; and GLS-5140 for the treatment of SFTS. In addition, it is developing GLS-5300, which is in Phase II clinical trial for MERS; GLS-5700 that is in Phase I clinical trial for Zika; and GLS-6150, which is in Phase I clinical trial for treatment of hepatitis C, as well as GLS-6100 that is in pre-clinical stage for hepatitis C. Further, the company, through its subsidiary, VGXI, Inc., engages in the cGMP production of nucleic acid-based products, including DNA plasmids and mRNA. The company was formerly known as VGX International Inc. and changed its name to GeneOne Life Science, Inc. in April 2014. GeneOne Life Science, Inc. was founded in 1976 and is headquartered in Seoul, South Korea.

Similar companies

096530.KQ

Seegene, Inc.

USD 17.02

-2.20%

006280.KS

Green Cross Corporation

USD 108.37

-2.33%

019170.KS

Shin Poong Pharm.Co.,Ltd.

USD 7.51

2.04%

001440.KS

Taihan Electric Wire Co., Ltd.

USD 8.75

2.33%

005690.KS

Pharmicell Co., Ltd.

USD 5.79

-4.44%

StockViz Staff

January 15, 2025

Any question? Send us an email